MedTrace Logo

Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

NCT04545008 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-02-18

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to assess the safety and toxicity profile of the combination of famotidine and oral n-acetyl cysteine in adult outpatients with newly diagnosed SARS-CoV-2 infection.

Conditions

  • Covid19

Interventions

DRUG

Famotidine

Oral Famotidine

DRUG

N-Acetyl cysteine

Oral N-Acetyl Cysteine

Sponsors & Collaborators

  • Clemson University

    collaborator OTHER

  • Prisma Health-Upstate

    lead OTHER

Principal Investigators

  • John J O'Connell, M.D. · Prisma Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2021-06-02
Completion
2021-06-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04545008 on ClinicalTrials.gov